ArticleParkinsonism & related disorders2026
Longitudinal brain morphometry in Parkinson's disease clinical subtypes: Distinct signatures forecast behavioral change within subtypes.
Article in Parkinsonism & related disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundParkinson's disease (PD) is clinically heterogenous. We previously identified a multi-domain classification of distinct PD subtypes in participants without dementia, yielding Motor Only, Psychiatric & Motor, and Cognitive & Motor subtypes. These PD subtypes may exhibit different rates of brain atrophy. We aim to determine baseline and longitudinal morphometric brain signatures of PD clinical subtypes and their relationship to behavioral change.
methods213 PD and 73 control participants completed T1-weighted structural MRIs and motor, cognitive, and psychiatric measures at baseline and every 1-3 years. We used FreeSurfer-v7.3 to obtain cortical thickness and brain volume measures, with manual edits as necessary. We used hierarchical linear models for longitudinal analyses-modeling time, subtype and their interaction; predictors include baseline age, motor symptom duration, sex, and education.
resultsMorphological brain MRI measures differentiate PD clinical subtypes at baseline, and the subtypes demonstrate different longitudinal rates of atrophy. The Motor Only subtype has preserved baseline morphometry and slow rate of atrophy, the Psychiatric & Motor has widespread baseline cortical thinning and slow rate of atrophy, and the Cognitive & Motor has baseline global and regional volume loss and fast rate of atrophy. Additionally, baseline morphometric measures predict longitudinal behavioral change within the Cognitive & Motor subtype.
conclusionMulti-domain PD clinical subtypes exhibit distinct baseline brain morphometric patterns and predictable longitudinal volumetric changes that substantiate previous observations of differential risks of progression, dementia, and death. These findings suggest underlying biological differences across subtypes that may help inform clinical expectations and guide clinical trial design.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.